A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumours and Titrated in Combination Therapy With Temodar for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas.

Trial Profile

A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumours and Titrated in Combination Therapy With Temodar for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Carboxyamidotriazole orotate (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Tactical Therapeutics
  • Most Recent Events

    • 07 Jun 2016 Results ((n=15) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top